A
Allen R. Chen
Researcher at Johns Hopkins University
Publications - 135
Citations - 6070
Allen R. Chen is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 33, co-authored 130 publications receiving 5244 citations. Previous affiliations of Allen R. Chen include Johns Hopkins University School of Medicine & Duke University.
Papers
More filters
Journal ArticleDOI
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik,Paul O'Donnell,Paul O'Donnell,Heather J. Symons,Allen R. Chen,M. Susan Leffell,Marianna Zahurak,Ted Gooley,Ted Gooley,S Piantadosi,Michele Kaup,Richard F. Ambinder,Carol Ann Huff,William Matsui,Javier Bolaños-Meade,Ivan Borrello,Jonathan D. Powell,Elizabeth Harrington,Sandy Warnock,Mary E.D. Flowers,Mary E.D. Flowers,Robert A. Brodsky,Brenda M. Sandmaier,Brenda M. Sandmaier,Rainer Storb,Rainer Storb,Richard J. Jones,Ephraim J. Fuchs +27 more
TL;DR: Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD, and there was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttrans transplantation Cy.
Journal ArticleDOI
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
Jason Coppell,Paul G. Richardson,Robert J. Soiffer,Paul L. Martin,Nancy A. Kernan,Allen R. Chen,Eva C. Guinan,Georgia B. Vogelsang,Amrita Krishnan,Sergio Giralt,Carolyn Revta,Nicole A. Carreau,Massimo Iacobelli,Enric Carreras,Tapani Ruutu,Tiziano Barbui,Joseph H. Antin,Dietger Niederwieser +17 more
TL;DR: The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome, and the methods used to evaluate severity are discussed.
Journal ArticleDOI
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
Leo Luznik,Javier Bolaños-Meade,Marianna Zahurak,Allen R. Chen,B. Douglas Smith,Robert A. Brodsky,Carol Ann Huff,Ivan Borrello,William Matsui,Jonathan D. Powell,Yvette L. Kasamon,Steven N. Goodman,Allan D. Hess,Hyam I. Levitsky,Richard F. Ambinder,Richard J. Jones,Ephraim J. Fuchs +16 more
TL;DR: High-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017).
Journal ArticleDOI
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Paul G. Richardson,Carol S. Murakami,Zhezhen Jin,Diane Warren,Parisa Momtaz,D. A. Hoppensteadt,Anthony D. Elias,Joseph H. Antin,Robert J. Soiffer,Thomas R. Spitzer,David Avigan,Scott I. Bearman,Paul L. Martin,Joanne Kurtzberg,James J. Vredenburgh,Allen R. Chen,Sally Arai,Georgia B. Vogelsang,George B. McDonald,Eva C. Guinan +19 more
TL;DR: The complete response rate, survival to day +100, and absence of significant DF-associated toxicity in this largest patient cohort reported to date confirm the results of earlier studies.
Journal ArticleDOI
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia
Robert Iannone,James F. Casella,Ephraim J. Fuchs,Allen R. Chen,Richard J. Jones,Ann E. Woolfrey,Michael D. Amylon,Keith M. Sullivan,Rainer Storb,Mark C. Walters +9 more
TL;DR: It is suggested that stable (full or partial) donor engraftment after nonmyeloablative hematopoietic stem cell transplantation (HCT) is more difficult to achieve among immunocompetent pediatric patients with hemoglobinopathies than among adults with hematologic malignancies.